Anika Therapeutics (ANIK) Cash from Operations (2010 - 2026)

Anika Therapeutics (ANIK) has reported Cash from Operations for 17 consecutive years, with -$684000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Operations fell 261.9% year-over-year to -$684000.0 in Q2 2026; TTM through Jun 2026 was $6.0 million, a 4.81% decrease from a year earlier, with the FY2025 full-year figure at $11.2 million, up 107.07% from the prior year.
• Cash from Operations was -$684000.0 for Q2 2026 at Anika Therapeutics, up from -$4.8 million in the prior quarter.
• Over five years, Cash from Operations peaked at $6.9 million in Q3 2025 and troughed at -$8.3 million in Q2 2023.
• A 5-year average of $760111.1 and a median of $177500.0 in 2022 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations surged 656.34% in 2023 and sank 3627.69% in 2026, its largest moves.
• Over 5 years, Cash from Operations stood at $481000.0 in 2022, then surged by 656.34% to $3.6 million in 2023, then plunged by 56.51% to $1.6 million in 2024, then surged by 193.11% to $4.6 million in 2025, then slumped by 114.75% to -$684000.0 in 2026.
• The last three Cash from Operations figures came in at -$684000.0 (Q2 2026), -$4.8 million (Q1 2026), and $4.6 million (Q4 2025), per Business Quant data.